# Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

> **NCT06164275** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 30 (estimated)

## Conditions studied

- Classic Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Multigated Acquisition Scan
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Vinblastine

## Key facts

- **NCT ID:** NCT06164275
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06164275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06164275, "Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06164275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*